 | • レポートコード：MRC2303E090 • 出版社/出版日：360iResearch / 2022年10月 • レポート形態：英語、PDF、234ページ • 納品方法：Eメール（受注後2-3日） • 産業分類：医療 |
| Single User（1名利用、印刷可） | ￥742,350 (USD4,949) | ▷ お問い合わせ |
| Enterprise License（企業利用、印刷可） | ￥1,492,350 (USD9,949) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| 360iResearch社は、2021年に4,432.35百万ドルであった世界の持続血糖モニタリング（CGM）システム市場規模が、2022年に4,956.31百万ドルに達し、2027年には8,794.97百万ドルまで年平均12.09%で成長すると予測しています。当調査レポートでは、持続血糖モニタリング（CGM）システムの世界市場について総合的に調査・分析を行い、序論、調査方法、エグゼクティブサマリー、市場概要、市場インサイト、コンポーネント別分析（一体型インスリンポンプ、センサー、送信機＆受信機）、人口統計別分析（成人人口、子供人口）、患者タイプ別分析（1型糖尿病、2型糖尿病）、エンドユーザー別分析（診断センター＆クリニック、在宅医療、ICU）、地域別分析（南北アメリカ、アメリカ、カナダ、ブラジル、アジア太平洋、日本、中国、インド、韓国、台湾、ヨーロッパ/中東/アフリカ、イギリス、ドイツ、フランス、ロシア、その他）、競争状況などの項目を掲載しています。なお、当書に掲載されている企業情報には、A. Menarini Diagnostics s.r.l、Abbott Laboratories、AgaMatrix Inc.、Ascensia Diabetes Care Holdings AG、Dexcom, Inc.、F. Hoffmann-La Roche Ltd.、GlySens Incorporated、Insulet Corporation、Johnson & Johnson Services, Inc.、Medtronic PLC、Medtrum Technologies Inc.、Nemaura Medical Inc.、Novo Nordisk A/Sなどが含まれています。 ・序論 ・調査方法 ・エグゼクティブサマリー ・市場概要 ・市場インサイト ・世界の持続血糖モニタリング（CGM）システム市場規模：コンポーネント別 - 一体型インスリンポンプの市場規模 - センサーの市場規模 - 送信機＆受信機の市場規模 ・世界の持続血糖モニタリング（CGM）システム市場規模：人口統計別 - 成人人口の市場規模 - 子供人口の市場規模 ・世界の持続血糖モニタリング（CGM）システム市場規模：患者タイプ別 - 1型糖尿病の市場規模 - 2型糖尿病の市場規模 ・世界の持続血糖モニタリング（CGM）システム市場規模：エンドユーザー別 - 診断センター＆クリニックにおける市場規模 - 在宅医療における市場規模 - ICUにおける市場規模 ・世界の持続血糖モニタリング（CGM）システム市場規模：地域別 - 南北アメリカの持続血糖モニタリング（CGM）システム市場規模 アメリカの持続血糖モニタリング（CGM）システム市場規模 カナダの持続血糖モニタリング（CGM）システム市場規模 ブラジルの持続血糖モニタリング（CGM）システム市場規模 ... - アジア太平洋の持続血糖モニタリング（CGM）システム市場規模 日本の持続血糖モニタリング（CGM）システム市場規模 中国の持続血糖モニタリング（CGM）システム市場規模 インドの持続血糖モニタリング（CGM）システム市場規模 韓国の持続血糖モニタリング（CGM）システム市場規模 台湾の持続血糖モニタリング（CGM）システム市場規模 ... - ヨーロッパ/中東/アフリカの持続血糖モニタリング（CGM）システム市場規模 イギリスの持続血糖モニタリング（CGM）システム市場規模 ドイツの持続血糖モニタリング（CGM）システム市場規模 インドの持続血糖モニタリング（CGM）システム市場規模 フランスの持続血糖モニタリング（CGM）システム市場規模 ロシアの持続血糖モニタリング（CGM）システム市場規模 ... - その他地域の持続血糖モニタリング（CGM）システム市場規模 ・競争状況 ・企業情報 |
The Global Continuous Glucose Monitoring Systems Market size was estimated at USD 4,432.35 million in 2021 and expected to reach USD 4,956.31 million in 2022, and is projected to grow at a CAGR 12.09% to reach USD 8,794.97 million by 2027.
Market Statistics:
The report provides market sizing and forecast across 7 major currencies – USD, EUR, JPY, GBP, AUD, CAD, and CHF. It helps organization leaders make better decisions when currency exchange data is readily available. In this report, the years 2018 and 2020 are considered as historical years, 2021 as the base year, 2022 as the estimated year, and years from 2023 to 2027 are considered as the forecast period.
Market Segmentation & Coverage:
This research report categorizes the Continuous Glucose Monitoring Systems to forecast the revenues and analyze the trends in each of the following sub-markets:
Based on Component, the market was studied across Integrated Insulin Pumps, Sensors, and Transmitters & Receivers.
Based on Demographics, the market was studied across Adult Population and Children Population.
Based on Patient Type, the market was studied across Type 1 Diabetes and Type 2 Diabetes.
Based on End User, the market was studied across Diagnostic Centers & Clinics, Home Healthcare, and ICUs.
Based on Distribution Channel, the market was studied across Institutional Sales and Retail Sales.
Based on Region, the market was studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Delaware, Georgia, Illinois, Minnesota, New Hampshire, Pennsylvania, Tennessee, Vermont, and Washington. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Algeria, Denmark, Egypt, Finland, France, Germany, Israel, Italy, Kenya, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Tanzania, Turkey, United Arab Emirates, and United Kingdom.
Cumulative Impact of COVID-19:
COVID-19 is an incomparable global public health emergency that has affected almost every industry, and the long-term effects are projected to impact the industry growth during the forecast period. Our ongoing research amplifies our research framework to ensure the inclusion of underlying COVID-19 issues and potential paths forward. The report delivers insights on COVID-19 considering the changes in consumer behavior and demand, purchasing patterns, re-routing of the supply chain, dynamics of current market forces, and the significant interventions of governments. The updated study provides insights, analysis, estimations, and forecasts, considering the COVID-19 impact on the market.
Cumulative Impact of 2022 Russia Ukraine Conflict:
We continuously monitor and update reports on political and economic uncertainty due to the Russian invasion of Ukraine. Negative impacts are significantly foreseen globally, especially across Eastern Europe, European Union, Eastern & Central Asia, and the United States. This contention has severely affected lives and livelihoods and represents far-reaching disruptions in trade dynamics. The potential effects of ongoing war and uncertainty in Eastern Europe are expected to have an adverse impact on the world economy, with especially long-term harsh effects on Russia.This report uncovers the impact of demand & supply, pricing variants, strategic uptake of vendors, and recommendations for Continuous Glucose Monitoring Systems market considering the current update on the conflict and its global response.
Competitive Strategic Window:
The Competitive Strategic Window analyses the competitive landscape in terms of markets, applications, and geographies to help the vendor define an alignment or fit between their capabilities and opportunities for future growth prospects. It describes the optimal or favorable fit for the vendors to adopt successive merger and acquisition strategies, geography expansion, research & development, and new product introduction strategies to execute further business expansion and growth during a forecast period.
FPNV Positioning Matrix:
The FPNV Positioning Matrix evaluates and categorizes the vendors in the Continuous Glucose Monitoring Systems Market based on Business Strategy (Business Growth, Industry Coverage, Financial Viability, and Channel Support) and Product Satisfaction (Value for Money, Ease of Use, Product Features, and Customer Support) that aids businesses in better decision making and understanding the competitive landscape.
Market Share Analysis:
The Market Share Analysis offers the analysis of vendors considering their contribution to the overall market. It provides the idea of its revenue generation into the overall market compared to other vendors in the space. It provides insights into how vendors are performing in terms of revenue generation and customer base compared to others. Knowing market share offers an idea of the size and competitiveness of the vendors for the base year. It reveals the market characteristics in terms of accumulation, fragmentation, dominance, and amalgamation traits.
Competitive Scenario:
The Competitive Scenario provides an outlook analysis of the various business growth strategies adopted by the vendors. The news covered in this section deliver valuable thoughts at the different stage while keeping up-to-date with the business and engage stakeholders in the economic debate. The competitive scenario represents press releases or news of the companies categorized into Merger & Acquisition, Agreement, Collaboration, & Partnership, New Product Launch & Enhancement, Investment & Funding, and Award, Recognition, & Expansion. All the news collected help vendor to understand the gaps in the marketplace and competitor’s strength and weakness thereby, providing insights to enhance product and service.
Company Usability Profiles:
The report profoundly explores the recent significant developments by the leading vendors and innovation profiles in the Global Continuous Glucose Monitoring Systems Market, including A. Menarini Diagnostics s.r.l, Abbott Laboratories, AgaMatrix Inc., Ascensia Diabetes Care Holdings AG, Dexcom, Inc., F. Hoffmann-La Roche Ltd., GlySens Incorporated, Insulet Corporation, Johnson & Johnson Services, Inc., Medtronic PLC, Medtrum Technologies Inc., Nemaura Medical Inc., Novo Nordisk A/S, NXP Semiconductors N.V., Senseonics Holdings Inc., STMicroelectronics, Tandem Diabetes Care, Inc., Texas Instruments Incorporated, and ViCentra B.V..
The report provides insights on the following pointers:
1. Market Penetration: Provides comprehensive information on the market offered by the key players
2. Market Development: Provides in-depth information about lucrative emerging markets and analyze penetration across mature segments of the markets
3. Market Diversification: Provides detailed information about new product launches, untapped geographies, recent developments, and investments
4. Competitive Assessment & Intelligence: Provides an exhaustive assessment of market shares, strategies, products, certification, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players
5. Product Development & Innovation: Provides intelligent insights on future technologies, R&D activities, and breakthrough product developments
The report answers questions such as:
1. What is the market size and forecast of the Global Continuous Glucose Monitoring Systems Market?
2. What are the inhibiting factors and impact of COVID-19 shaping the Global Continuous Glucose Monitoring Systems Market during the forecast period?
3. Which are the products/segments/applications/areas to invest in over the forecast period in the Global Continuous Glucose Monitoring Systems Market?
4. What is the competitive strategic window for opportunities in the Global Continuous Glucose Monitoring Systems Market?
5. What are the technology trends and regulatory frameworks in the Global Continuous Glucose Monitoring Systems Market?
6. What is the market share of the leading vendors in the Global Continuous Glucose Monitoring Systems Market?
7. What modes and strategic moves are considered suitable for entering the Global Continuous Glucose Monitoring Systems Market?
1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Limitations
1.7. Assumptions
1.8. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
5. Market Insights
5.1. Market Dynamics
5.1.1. Drivers
5.1.1.1. Increasing Number of Incidence of Diabetic Patients Globally
5.1.1.2. Growing Regulatory Approvals for the CGM Systems
5.1.1.3. Growing Adoption Rate of CGM Systems in Home Healthcare
5.1.2. Restraints
5.1.2.1. Occurrence of Adverse Effects and Limited Accuracy of CGM Devices
5.1.3. Opportunities
5.1.3.1. Technological Advancements and Increased Awareness of CGM Systems
5.1.3.2. Rising Preferences for Non-invasive Methods and Potential Undiagnosed Patient Population
5.1.4. Challenges
5.1.4.1. Reimbursement and Stringent Regulatory Issues
5.2. Cumulative Impact of COVID-19
6. Continuous Glucose Monitoring Systems Market, by Component
6.1. Introduction
6.2. Integrated Insulin Pumps
6.3. Sensors
6.4. Transmitters & Receivers
7. Continuous Glucose Monitoring Systems Market, by Demographics
7.1. Introduction
7.2. Adult Population
7.3. Children Population
8. Continuous Glucose Monitoring Systems Market, by Patient Type
8.1. Introduction
8.2. Type 1 Diabetes
8.3. Type 2 Diabetes
9. Continuous Glucose Monitoring Systems Market, by End User
9.1. Introduction
9.2. Diagnostic Centers & Clinics
9.3. Home Healthcare
9.4. ICUs
10. Continuous Glucose Monitoring Systems Market, by Distribution Channel
10.1. Introduction
10.2. Institutional Sales
10.3. Retail Sales
11. Americas Continuous Glucose Monitoring Systems Market
11.1. Introduction
11.2. Argentina
11.3. Brazil
11.4. Canada
11.5. Mexico
11.6. United States
12. Asia-Pacific Continuous Glucose Monitoring Systems Market
12.1. Introduction
12.2. Australia
12.3. China
12.4. India
12.5. Indonesia
12.6. Japan
12.7. Malaysia
12.8. Philippines
12.9. Singapore
12.10. South Korea
12.11. Taiwan
12.12. Thailand
12.13. Vietnam
13. Europe, Middle East & Africa Continuous Glucose Monitoring Systems Market
13.1. Introduction
13.2. Algeria
13.3. Denmark
13.4. Egypt
13.5. Finland
13.6. France
13.7. Germany
13.8. Israel
13.9. Italy
13.10. Kenya
13.11. Netherlands
13.12. Nigeria
13.13. Norway
13.14. Poland
13.15. Qatar
13.16. Russia
13.17. Saudi Arabia
13.18. South Africa
13.19. Spain
13.20. Sweden
13.21. Switzerland
13.22. Tanzania
13.23. Turkey
13.24. United Arab Emirates
13.25. United Kingdom
14. Competitive Landscape
14.1. FPNV Positioning Matrix
14.1.1. Quadrants
14.1.2. Business Strategy
14.1.3. Product Satisfaction
14.2. Market Ranking Analysis, By Key Player
14.3. Market Share Analysis, By Key Player
14.4. Competitive Scenario
14.4.1. Merger & Acquisition
14.4.2. Agreement, Collaboration, & Partnership
14.4.3. New Product Launch & Enhancement
14.4.4. Investment & Funding
14.4.5. Award, Recognition, & Expansion
15. Company Usability Profiles
15.1. A. Menarini Diagnostics s.r.l
15.1.1. Business Overview
15.1.2. Key Executives
15.1.3. Product & Services
15.2. Abbott Laboratories
15.2.1. Business Overview
15.2.2. Key Executives
15.2.3. Product & Services
15.3. AgaMatrix Inc.
15.3.1. Business Overview
15.3.2. Key Executives
15.3.3. Product & Services
15.4. Ascensia Diabetes Care Holdings AG
15.4.1. Business Overview
15.4.2. Key Executives
15.4.3. Product & Services
15.5. Dexcom, Inc.
15.5.1. Business Overview
15.5.2. Key Executives
15.5.3. Product & Services
15.6. F. Hoffmann-La Roche Ltd.
15.6.1. Business Overview
15.6.2. Key Executives
15.6.3. Product & Services
15.7. GlySens Incorporated
15.7.1. Business Overview
15.7.2. Key Executives
15.7.3. Product & Services
15.8. Insulet Corporation
15.8.1. Business Overview
15.8.2. Key Executives
15.8.3. Product & Services
15.9. Johnson & Johnson Services, Inc.
15.9.1. Business Overview
15.9.2. Key Executives
15.9.3. Product & Services
15.10. Medtronic PLC
15.10.1. Business Overview
15.10.2. Key Executives
15.10.3. Product & Services
15.11. Medtrum Technologies Inc.
15.11.1. Business Overview
15.11.2. Key Executives
15.11.3. Product & Services
15.12. Nemaura Medical Inc.
15.12.1. Business Overview
15.12.2. Key Executives
15.12.3. Product & Services
15.13. Novo Nordisk A/S
15.13.1. Business Overview
15.13.2. Key Executives
15.13.3. Product & Services
15.14. NXP Semiconductors N.V.
15.14.1. Business Overview
15.14.2. Key Executives
15.14.3. Product & Services
15.15. Senseonics Holdings Inc.
15.15.1. Business Overview
15.15.2. Key Executives
15.15.3. Product & Services
15.16. STMicroelectronics
15.16.1. Business Overview
15.16.2. Key Executives
15.16.3. Product & Services
15.17. Tandem Diabetes Care, Inc.
15.17.1. Business Overview
15.17.2. Key Executives
15.17.3. Product & Services
15.18. Texas Instruments Incorporated
15.18.1. Business Overview
15.18.2. Key Executives
15.18.3. Product & Services
15.19. ViCentra B.V.
15.19.1. Business Overview
15.19.2. Key Executives
15.19.3. Product & Services
16. Appendix
16.1. Discussion Guide
16.2. License & Pricing